BMB-201

Uses your system voice; voice and rate in settings.

Snapshot

≈ 3 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

BMB-201 is a serotonin 5-HT 2A and 5-HT 2C receptor agonist of the tryptamine family described as a non-hallucinogenic psychoplastogen which is under development for the treatment of depression, anxiety, pain, and other indications. Its route of administration is unspecified.

BMB-201 is a serotonin 5-HT 2A and 5-HT 2C receptor agonist of the tryptamine family described as a non-hallucinogenic psychoplastogen which is under development for the treatment of depression, anxiety, pain, and other indications. Its route of administration is unspecified.

Pharmacology

BMB-201 is a prodrug of another compound known as BMB-A39a. This active metabolite acts as a biased partial agonist of the serotonin 5-HT 2A and 5-HT 2C receptors. BMB-A39a is slightly less efficacious in activating G q signaling at the serotonin 5-HT 2A and 5-HT 2C receptors compared to psilocin ( = 68% vs. 82% at 5-HT 2A and 79% vs. 95% at 5-HT 2C , respectively). It is about 9-fold less potent in activating the serotonin 5-HT 2A receptor than psilocin, whereas its potency in activating the serotonin 5-HT 2C receptor is similar to that of psilocin.

Relatedly, whereas psilocin shows balanced activation of both the serotonin 5-HT 2A and 5-HT 2C receptors, BMB-A39a is about 11-fold more potent in activating the serotonin 5-HT 2C receptor over the serotonin 5-HT 2A receptor. In addition to the serotonin 5-HT 2A and 5-HT 2C receptors, BMB-A39a is a potent partial agonist of the serotonin 5-HT 1F and 5-HT 6 receptors. On the other hand, it shows minimal or negligible activity in activating the serotonin 5-HT 2B receptor ( 1B and 5-HT 1D receptors.

BMB-A39a shows less than 70% efficacy in activating G q signaling at the serotonin 5-HT 2A receptor, which has been associated with absence of hallucinogenic-like activity. Accordingly, BMB-201 is said to have minimal or absent psychedelic effects due to its reduced serotonin 5-HT 2A receptor intrinsic activity but to potently induce neuroplasticity. It has been reported to show effectiveness in animal models of depression, anxiety, pain, and substance use disorder.

Chemistry

pharmacology as BMB-A39a patented by Bright Minds Biosciences. 7-Methyl psilocybin was also patented. The exact chemical structure of BMB-201 does not yet appear to have been disclosed. However, it is known to be a tryptamine derivative. In addition, Bright Mind Biosciences has patented tryptamines and prodrugs as serotonin 5-HT 2 receptor modulators, including for example 7-methylpsilocin and 7-methylpsilocybin.

Research

BMB-201 is under development by Bright Minds Biosciences. As of September 2025, it is in the preclinical research stage of development for the treatment of depressive disorders and pain.

See also

List of investigational hallucinogens and entactogens Substituted tryptamine Non-hallucinogenic 5-HT 2A receptor agonist BMB-101 BMB-105 BMB-202 Pharm-136

References

External links

Pipeline - Bright Minds Biosciences 7-Methylpsilocin - Isomer Design

Text derived from https://en.wikipedia.org/w/index.php?oldid=1368835124 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

11 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.